Reported Earlier, Mesoblast Reaches Patient Recruitment Target In Phase 3 Trial For Non-Opioid Chronic Low Back Pain Therapy
Reported Earlier, Mesoblast Acquires Exclusive Worldwide License To Mayo Clinic-Developed CAR Technology Platform To Boost Effectiveness Of MSC Products For Inflammatory Diseases
Mesoblast Limited: A Risk/Reward Story
Mesoblast Receives Investigational New Drug Clearance From FDA For Registrational Clinical Trial For Duchenne Muscular Dystrophy Treatment Ryoncil
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
Reported Earlier, Mesoblast's FDA-Approved Ryoncil Gets IND Clearance For Registrational DMD Trial, To Randomize 76 Patients Aged 5-9 Years Across 7 Infusions Over 9 Months
Reported Earlier, Mesoblast Reports $30.3M In Ryoncil Net Sales For March Quarter As Strong February And March Growth Offsets January Holiday Seasonality
Mesoblast shares are trading lower after the company reported worse-than-expected Q4 sales results.
Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
What's Next: Mesoblast's Earnings Preview
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Reported Earlier, Mesoblast Data Shows 15% Early Mortality In Third-Line Ryoncil Treatment Versus 2% In Second-Line Phase 3 Trial Emphasizing Earlier Use Importance
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
ASX Growth Companies With High Insider Stakes To Watch
Reported Earlier, Mesoblast Highlights Ryoncil Net Revenues Of $30M With Strong Sales Momentum And Enhanced Strategic Optionality
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.